EMEA-002029-PIP01-16-M01

Key facts

Active substance
Tremelimumab
Therapeutic area
Oncology
Decision number
P/0245/2019
PIP number
EMEA-002029-PIP01-16-M01
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
  • Treatment of all conditions included in the category of malignant neoplasms (excluding central nervous system, haematopoietic and lymphoid tissue neoplasms)
  • Treatment of malignant neoplasms of haematopoietic and lymphoid tissue
Route(s) of administration
Intravenous use
Contact for public enquiries
AstraZeneca AB (Sweden)

Tel. +46 8553 27591
E-mail: paediatrics@astrazeneca.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating
Average
1 rating